Loading viewer...
investor_presentation
Format: PDF investor_presentation
enVVeno Medical is developing innovative surgical and non-surgical replacement venous valves to treat chronic venous insufficiency (CVI), addressing a market of over 6 million potential U.S. patients. The company is advancing its VenoValve® device through the SAVVE U.S. pivotal trial and upcoming TAVVE first-in-human studies, with sufficient capital to fund operations through 2024.
investor_presentation
28 Pages
investor_presentation
34 Pages
Reliance
investor_presentation
ANALOGUE Holdings